Diverse underlying proliferation response to growth factors in imatinib-treated Philadelphia chromosome-positive leukemias

作者：Nemoto Atsushi; Inukai Takeshi^*; Uno Kanako; Kiyokawa Nobutaka; Miyagawa Yoshitaka; Takahashi Kazuya; Sato Hiroki; Akahane Koshi; Hirose Kinuko; Honna Oshiro Hiroko; Goi Kumiko; Kagami Keiko; Nakazawa Shinpei; Fujimoto Junichiro; Inaba Toshiya; Sugita Kanji

来源：Leukemia Research, 2013, 37(1): 93-101.

DOI：10.1016/j.leukres.2012.10.001

• Philadelphia chromosome-positive leukemia
• BCR-ABL
• Imatinib
• Growth factor
• Human hematopoiesis

Since BCR-ABL plays an essential role in the growth factor-independent proliferation of Philadelphia chromosome (Ph)+leukemia cells, imatinib treatment of Ph+leukemia cells inactivates signaling pathways of BCR-ABL, and subsequent addition of growth factors (GFs) could restore the signaling pathways without reactivating BCR-ABL. Here we demonstrated that non-lymphoid Ph+leukemia cell lines responded to diverse GFs depending on their immunophenotype and gene expression of transcription factors and GF receptors, while lymphoid Ph+leukemia cell lines restrictively responded to flit3 ligand and interleukin-7, suggesting that GF sensitivity of imatinib-treated Ph+leukemia cells could be powerful for specifying their distinctive lineage.

• 出版日期2013-1